NSEResignation11 Sept 2026 · 11 Sept 2026, 04:09 pm
Resignation
Eris Lifesciences Limited · ERIS
✦ AI SummaryMgmt Change
Eris Lifesciences Limited has announced the resignation of Mr. Krishnakumar Vaidyanathan as Executive Director and Chief Operating Officer (COO) effective September 30, 2026, to pursue professional opportunities outside the organization.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Eris Lifesciences Limited has informed the Exchange regarding Resignation of Mr Krishnakumar Vaidyanathan as Executive Director of the company w.e.f. September 30, 2026.
Attachments (1)
📄pdf
Download →
ERIS_11092026160851_Intimationsigned.pdf
View document text
Date: 11 September 2026
To To
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza
Dalal Street Bandra Kurla Complex
Mumbai- 400001 Bandra (E)
Mumbai-400051
Security Code: 540596 Symbol: ERIS
SUBJECT: INTIMATION UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE
REQUIREMENTS) REGULATIONS, 2015 – RESIGNATION OF EXECUTIVE DIRECTOR & CHIEF
OPERATING OFFICER (COO)
Dear Sir/Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we
wish to inform you that Mr. Krishnakumar Vaidyanathan has tendered his resignation from the position of Executive
Director & Chief Operating Officer (COO) of the Company.
He has decided to step down to pursue professional opportunities outside the organization. The resignation has
been accepted by the Chairman. Consequently, the Company has decided to relieve him from his duties with effect
from the close of business hours on September 30, 2026.
The Company places on record its sincere appreciation for the valuable contributions, leadership, and dedication
demonstrated by Mr. Krishnakumar Vaidyanathan during his tenure with the organization.
In accordance with requirement of regulation 30 of the Securities and Exchange Board of India (Listing Obligations
and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III and SEBI Master
Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, details attached herein shall be
taken on record.
You are requested to take the above information on your record.
Thanking You,
For Eris Lifesciences Limited
Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493
Encl: As above
Annexure
Sr. No. Particulars Details
1. Reason for change viz. appointment, re- Resignation to pursue professional opportunities
appointment, resignation, removal, death or outside the Company.
otherwise:
2. Date of appointment/re-appointment/cessation (as Close of business hours on September 30, 2026
applicable) & term of appointment/re-appointment:
3. Brief profile (in case of appointment): Not Applicable
4. Disclosure of relationships between directors (in Not Applicable
case of appointment of a director):